MA42045A - Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers - Google Patents
Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancersInfo
- Publication number
- MA42045A MA42045A MA042045A MA42045A MA42045A MA 42045 A MA42045 A MA 42045A MA 042045 A MA042045 A MA 042045A MA 42045 A MA42045 A MA 42045A MA 42045 A MA42045 A MA 42045A
- Authority
- MA
- Morocco
- Prior art keywords
- peptides
- cancers
- crc
- combinations
- present
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000009030 Carcinoma Diseases 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 title 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 title 1
- 201000010989 colorectal carcinoma Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des peptides, des protéines, des acides nucléiques et des cellules destinés à être utilisés dans des procédés immunothérapeutiques. La présente invention concerne en particulier l'immunothérapie du cancer. La présente invention concerne en outre des épitopes peptidiques de cellules t associés à une tumeur, seuls ou combinés à d'autres peptides associés à une tumeur, qui peuvent par exemple servir de principes actifs pharmaceutiques de compositions vaccinales qui stimulent des réponses immunitaires antitumorales, ou pour stimuler des cellules t ex vivo et les transférer dans des patients. Des peptides liés aux molécules du complexe majeur d'histocompatibilité (cmh), ou des peptides tels quels, peuvent également être des cibles d'anticorps, des récepteurs de cellules t solubles et d'autres molécules de liaison.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562157684P | 2015-05-06 | 2015-05-06 | |
GBGB1507719.1A GB201507719D0 (en) | 2015-05-06 | 2015-05-06 | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
PCT/EP2016/060007 WO2016177784A1 (fr) | 2015-05-06 | 2016-05-04 | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
MA42045A true MA42045A (fr) | 2018-03-14 |
MA42045B1 MA42045B1 (fr) | 2021-04-30 |
Family
ID=53489186
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41393A MA41393B2 (fr) | 2015-05-06 | 2016-05-04 | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers |
MA43322A MA43322A1 (fr) | 2015-05-06 | 2016-05-04 | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers |
MA42045A MA42045B1 (fr) | 2015-05-06 | 2016-05-04 | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers |
MA053033A MA53033A (fr) | 2015-05-06 | 2016-05-04 | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41393A MA41393B2 (fr) | 2015-05-06 | 2016-05-04 | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers |
MA43322A MA43322A1 (fr) | 2015-05-06 | 2016-05-04 | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053033A MA53033A (fr) | 2015-05-06 | 2016-05-04 | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers |
Country Status (27)
Country | Link |
---|---|
US (9) | US10221225B2 (fr) |
EP (2) | EP3291830B1 (fr) |
JP (1) | JP7513561B2 (fr) |
KR (1) | KR20170141214A (fr) |
CN (1) | CN113527421A (fr) |
AU (9) | AU2016258965B2 (fr) |
BR (1) | BR112017023362A2 (fr) |
CA (1) | CA2984123A1 (fr) |
CR (1) | CR20170497A (fr) |
DK (1) | DK3291830T3 (fr) |
EA (1) | EA201792242A1 (fr) |
ES (1) | ES2860798T3 (fr) |
GB (1) | GB201507719D0 (fr) |
HU (1) | HUE053807T2 (fr) |
LT (1) | LT3291830T (fr) |
MA (4) | MA41393B2 (fr) |
MD (1) | MD3291830T2 (fr) |
MX (1) | MX2017014008A (fr) |
PE (1) | PE20180487A1 (fr) |
PL (1) | PL3291830T3 (fr) |
PT (1) | PT3291830T (fr) |
RS (1) | RS61667B1 (fr) |
SG (2) | SG11201708571YA (fr) |
SI (1) | SI3291830T1 (fr) |
TW (1) | TWI725026B (fr) |
UA (1) | UA123941C2 (fr) |
WO (1) | WO2016177784A1 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
MD3236985T3 (ro) | 2014-12-23 | 2023-03-31 | Immatics Biotechnologies Gmbh | Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și altor tipuri de cancere |
MY198087A (en) * | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
BR112018012374A2 (pt) | 2015-12-16 | 2018-12-04 | Gritstone Oncology, Inc. | identificação, fabricação e uso de neoantígeno |
GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
KR101925125B1 (ko) * | 2016-06-16 | 2018-12-04 | 울산대학교 산학협력단 | Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 |
KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
WO2018119351A1 (fr) | 2016-12-23 | 2018-06-28 | Bluefin Biomedicine, Inc. | Anticorps anti-sez6l2 et conjugués anticorps-médicaments |
US10429364B2 (en) * | 2017-01-31 | 2019-10-01 | Thermo Finnigan Llc | Detecting low level LCMS components by chromatographic reconstruction |
DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
EP3694532A4 (fr) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | Identification de néo-antigènes au moyen de points chauds |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
WO2019157298A1 (fr) | 2018-02-09 | 2019-08-15 | Immatics US, Inc. | Procédés de fabrication de lymphocytes t |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
BR112022016909A2 (pt) | 2020-02-24 | 2022-12-06 | Immatics Us Inc | Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
WO2022040631A1 (fr) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Procédés d'isolement de lymphocytes t sélectionnés cd8+ |
WO2022125686A1 (fr) | 2020-12-08 | 2022-06-16 | Government Of The United States Of America, As Represented By The Secretary Of Commerce | Ingénierie de précision d'une fonction de détection et de réponse cellulaire |
JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | Cd8ポリペプチド、組成物、及びそれらの使用方法 |
US20220356252A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
EP4392441A1 (fr) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel |
WO2023044488A1 (fr) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Déplétion monocytaire des populations de lymphocytes t pour une thérapie par lymphocytes t |
CN114107507B (zh) * | 2021-09-29 | 2023-04-25 | 暨南大学 | Zswim1蛋白在调控肺腺癌细胞增殖和转移中的应用 |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212655A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation |
WO2023212697A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation |
WO2023215825A1 (fr) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Procédés d'amélioration de l'efficacité d'un lymphocyte t |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
IN151589B (fr) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
FR2677653A1 (fr) * | 1991-06-17 | 1992-12-18 | Inst Nat Sante Rech Med | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. |
AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
AU1394497A (en) | 1996-01-17 | 1997-08-11 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
US5891857A (en) * | 1996-02-20 | 1999-04-06 | Vanderbilt University | Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6773878B1 (en) * | 1999-11-09 | 2004-08-10 | Eos Biotechnology, Inc. | Methods of diagnosing of colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
EP1290217A2 (fr) * | 2000-02-04 | 2003-03-12 | Aeomica, Inc. | Procedes et appareil destines a predire, a confirmer, et a afficher des informations fonctionnelles derivees d'une sequence genomique |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
CA2404489A1 (fr) | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Complexes majeurs d'histocompatibilite monocatenaires de classe 1, constructions les codant et leurs methodes de production |
CN101712721A (zh) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
AU2002211665B2 (en) | 2000-10-12 | 2005-10-20 | Exelixis, Inc. | Human Ect2 and methods of use |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
WO2003070752A2 (fr) | 2002-02-20 | 2003-08-28 | Dyax Corporation | Ligands de liaison au complexe mhc-peptide |
EP1549748B1 (fr) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Recepteurs de lymphocytes t de recombinaison a chaine unique |
SE0203137D0 (sv) * | 2002-10-24 | 2002-10-24 | Karolinska Innovations Ab | Drug target in cancer therapy |
NZ570811A (en) | 2002-11-09 | 2009-11-27 | Immunocore Ltd | T cell receptor display |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
WO2004108964A1 (fr) * | 2003-06-04 | 2004-12-16 | Agency For Science, Technology And Research | Genes de carcinome hepatocellulaire a regulation differentielle et leurs utilisations |
GB0402904D0 (en) | 2004-02-10 | 2004-03-17 | Cyclacel Ltd | Polypeptide |
DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
SI1806359T1 (sl) | 2005-09-05 | 2010-06-30 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II |
CN101168566A (zh) * | 2006-10-26 | 2008-04-30 | 北京市肿瘤防治研究所 | 抗肿瘤特异性标志蛋白ts/medp的抗体制备及用途 |
TWI610939B (zh) | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
CA2694805C (fr) * | 2007-07-27 | 2014-09-09 | Immatics Biotechnologies Gmbh | Nouveaux epitopes immunogenes destines a l'immunotherapie |
US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
EP2172211B1 (fr) | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers |
US20120231007A1 (en) | 2009-11-23 | 2012-09-13 | Singapore Health Services Pte. Ltd. | Modulators of cell cycle progression |
WO2013040142A2 (fr) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Procédés bio-informatiques de détermination de liaisons peptidiques |
TWI538685B (zh) | 2010-04-02 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Ect2胜肽及含此胜肽之疫苗 |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
BR112013010213A2 (pt) | 2010-10-26 | 2019-09-24 | Technion Research & Development Foundation Ltd | anticorpos que unem ligantes solúveis de receptores de célula t |
WO2013057586A1 (fr) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions et procédés de production de récepteurs solubles des lymphocytes t |
WO2014071978A1 (fr) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Acides nucléiques codant pour des polypeptides chimériques pour criblage de banque |
EP2808392A1 (fr) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer |
TWI775117B (zh) | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(二) |
GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
-
2015
- 2015-05-06 GB GBGB1507719.1A patent/GB201507719D0/en not_active Ceased
-
2016
- 2016-05-04 PE PE2017002366A patent/PE20180487A1/es unknown
- 2016-05-04 CN CN202110645719.0A patent/CN113527421A/zh active Pending
- 2016-05-04 RS RS20210416A patent/RS61667B1/sr unknown
- 2016-05-04 EP EP16723966.4A patent/EP3291830B1/fr active Active
- 2016-05-04 PL PL16723966T patent/PL3291830T3/pl unknown
- 2016-05-04 SG SG11201708571YA patent/SG11201708571YA/en unknown
- 2016-05-04 LT LTEP16723966.4T patent/LT3291830T/lt unknown
- 2016-05-04 SI SI201631142T patent/SI3291830T1/sl unknown
- 2016-05-04 SG SG10202013230PA patent/SG10202013230PA/en unknown
- 2016-05-04 EA EA201792242A patent/EA201792242A1/ru unknown
- 2016-05-04 MA MA41393A patent/MA41393B2/fr unknown
- 2016-05-04 WO PCT/EP2016/060007 patent/WO2016177784A1/fr active Application Filing
- 2016-05-04 PT PT167239664T patent/PT3291830T/pt unknown
- 2016-05-04 EP EP20206485.3A patent/EP3815712A1/fr active Pending
- 2016-05-04 MA MA43322A patent/MA43322A1/fr unknown
- 2016-05-04 MX MX2017014008A patent/MX2017014008A/es unknown
- 2016-05-04 US US15/145,936 patent/US10221225B2/en active Active
- 2016-05-04 CA CA2984123A patent/CA2984123A1/fr active Pending
- 2016-05-04 HU HUE16723966A patent/HUE053807T2/hu unknown
- 2016-05-04 ES ES16723966T patent/ES2860798T3/es active Active
- 2016-05-04 AU AU2016258965A patent/AU2016258965B2/en active Active
- 2016-05-04 MD MDE20180258T patent/MD3291830T2/ro unknown
- 2016-05-04 MA MA42045A patent/MA42045B1/fr unknown
- 2016-05-04 US US15/145,999 patent/US10457712B2/en active Active
- 2016-05-04 MA MA053033A patent/MA53033A/fr unknown
- 2016-05-04 CR CR20170497A patent/CR20170497A/es unknown
- 2016-05-04 KR KR1020177031972A patent/KR20170141214A/ko not_active Application Discontinuation
- 2016-05-04 BR BR112017023362-2A patent/BR112017023362A2/pt active Search and Examination
- 2016-05-04 UA UAA201710276A patent/UA123941C2/uk unknown
- 2016-05-04 US US15/145,990 patent/US10526386B2/en active Active
- 2016-05-04 DK DK16723966.4T patent/DK3291830T3/da active
- 2016-05-06 TW TW105114152A patent/TWI725026B/zh active
-
2018
- 2018-05-14 US US15/979,012 patent/US10435448B2/en active Active
- 2018-05-14 US US15/979,089 patent/US10442844B2/en active Active
- 2018-05-17 US US15/982,397 patent/US10513547B2/en active Active
-
2019
- 2019-08-30 US US16/556,693 patent/US11597752B2/en active Active
- 2019-10-02 US US16/591,158 patent/US20200024317A1/en not_active Abandoned
-
2020
- 2020-09-29 AU AU2020244418A patent/AU2020244418B2/en active Active
- 2020-09-29 AU AU2020244420A patent/AU2020244420B2/en active Active
- 2020-09-29 AU AU2020244424A patent/AU2020244424B2/en active Active
- 2020-09-29 AU AU2020244419A patent/AU2020244419B2/en active Active
- 2020-09-29 AU AU2020244423A patent/AU2020244423A1/en not_active Abandoned
- 2020-09-29 AU AU2020244421A patent/AU2020244421B2/en active Active
- 2020-09-29 AU AU2020244422A patent/AU2020244422B2/en active Active
- 2020-09-29 AU AU2020244417A patent/AU2020244417B2/en active Active
-
2021
- 2021-03-31 JP JP2021059554A patent/JP7513561B2/ja active Active
- 2021-06-18 US US17/351,341 patent/US20210317175A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42045A (fr) | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers | |
MA46022A (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers | |
MA43490A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
MA43327A1 (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et d'autres cancers | |
MA43435B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003) | |
MA44101A (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
MA41520B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA43457A1 (fr) | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers | |
MA46647A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
MA46508A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
MA42294B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA44551A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers | |
MA43090A1 (fr) | Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers | |
MA43330A1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
MA43328A1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
MA41522A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l'œsophage et d'autres cancers | |
MA41237B1 (fr) | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers | |
MA47367B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA46913B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers | |
MA41664A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers | |
MA46503A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers |